The 2024 annual report recently released by Ruipu Bio shows that the company adheres to technological innovation and strategic layout, and achieves operating income of 3.07 billion yuan, a year-on-year increase of 13.32%; net profit attributable to shareholders of listed companies is 301 million yuan; it plans to pay 3 yuan (including tax) for every 10 shares.

In 2024, the company invested 238 million yuan in research and development, accounting for 7.76% of operating income, and added 10 new veterinary drug registration certificates and 29 authorized patents. In the field of biological products, cutting-edge technologies such as mRNA technology platform and recombinant duck plague virus vector vaccine have made breakthroughs. Among them, the independently developed cat triple vaccine "Ruimiaoshu" has become the first local listed product. The enrofloxacin hydrochloride pellet coating preparation developed by the Drug Research Institute reduces the cost of medication by 25%-50%, which is highly recognized by the industry.

In addition, the company has completed the registration of 35 products, Tianjin and Gaoke companies have passed the Indonesian GMP audit, and Betway Antai has passed the Thai GMP certification. Throughout the year, we have reached cooperation with more than 20 group customers at the 10 million level, created 50 large single products at the 10 million level, and deepened strategic cooperation with leading companies such as Dekang Agriculture and Animal Husbandry and Shengnong Development to build an industrial ecosystem.

Looking to the future, Ruipu Bio will continue to deepen the research and development of technologies such as mRNA, genetic engineering vaccines, and innovative drugs to promote the industrialization of synthetic biology; accelerate the layout of pets, rumination and other fields, and build a full chain of "research and development-production-service"; conduct mergers and acquisitions of key products, key processes, and key technologies to improve product competitiveness and increase product market share; take the cross-border extension of core technologies as the main line, and through the mergers and acquisitions of technologies, products, channels, and brands in the fields of pets and synthetic biology, realize the construction and expansion of the company's second growth curve; through investment, we will form a closer cooperative relationship with customers and build a good industrial development ecology. The company will take technological innovation as the core driving force and continue to create value for shareholders.

https://finance.eastmoney.com/a/202504093371520652.html